

AMENDMENTS TO THE SPECIFICATION

Please amend the specification by rewriting the following paragraphs, as set forth below in marked-up form. Applicant has also submitted a revised page 13 of the specification which incorporates the changes shown below.

In the paragraph beginning on page 13, line 4,

--As a model peptide, laminin pentapeptide (PEPTIDE INSTITUTE, Inc.) was used. The amino acid sequence of the laminin pentapeptide is as follows: Tyr-Ile-Gly-Ser-Arg-NH₂ (SEQ ID NO: 1). In this sequence, the arginine residue is amidated and is represented as Arg-NH₂. 2μl of 1mM dimethylformamide solution of N-biotinylcysteic acid, 0.6μl of dimethylformamide solution containing 0.5M HBTU (2-[1H-benzotriazole-1-yl]-1,1,3,3- tetramethyluronium hexafluorophosphate) and 0.5M HOBr (N-hydroxybenzotriazole), and 0.6μl of 1M dimethylformamide solution of diisopropylethylamine were mixed with one another. The mixture was then added to 2μl of 2mM dimethylformamide solution of laminin pentapeptide, and the reaction was allowed to proceed at room temperature for 30min. After the reaction was completed, the reaction mixture was diluted with 0.1w% aqueous solution of trifluoroacetic acid and was subjected to PSD analysis by MALDI-TOF MS.--